Abstract
There are numerous causes of acute and chronic kidney disease following HSCT. Excluding nephrotoxic drugs and infections, the role of GVHD in the genesis of several glomerulopathies is a controversial or incompletely understood subject. Transplant-associated thrombotic microangiopathy (TA-TMA) has been associated with exposure to calcineurin inhibitors (CNIs) in earlier studies, and more recent studies have demonstrated associations with GVHD. Many of these processes can coexist, making etiologic determination difficult. The development of TA-TMA has not been conclusively linked with the use of high-dose conditioning regimens nor has a clear or consistent response to anticomplement treatment (e.g., eculizumab) been observed. Other post-HSCT glomerulopathies associated with nephrotic syndrome include membranous nephropathy, minimal change disease, and focal segmental glomerulosclerosis (FSGS). The potential mechanisms of GVHD’s role in kidney injury, e.g., the contributions of T cells, macrophages, cytokines, and immune responses against kidney proteins, require further investigation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bruno B, Zager RA, Boeckh MJ, et al. Adenovirus nephritis in hematopoietic stem-cell transplantation. Transplantation. 2004;77(7):1049–57.
Haines HL, Laskin BL, Goebel J, et al. Blood, and not urine, BK viral load predicts renal outcome in children with hemorrhagic cystitis following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(10):1512–9.
Laskin BL, Goebel J, Davies SM, et al. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2011;46(5):682–9.
Jodele S, Davies SM, Lane A, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124(4):645–53.
Jodele S, Bleesing JJ, Mehta PA, et al. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2012;16(2):E39–42.
Hingorani SR, Seidel K, Pao E, Lawler R, McDonald GB. Markers of coagulation activation and acute kidney injury in patients after hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50(5):715–20.
Jodele S, Licht C, Goebel J, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013;122(12):2003–7.
Laskin BL, Maisel J, Goebel J, et al. Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation. 2013;96(2):217–23.
Hingorani S. Renal complications of hematopoietic-cell transplantation. N Engl J Med. 2016;374(23):2256–67.
Rosenthal J, Pawlowska A, Bolotin E, et al. Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus. Pediatr Blood Cancer. 2011;57(1):142–6.
Changsirikulchai S, Myerson D, Guthrie KA, McDonald GB, Alpers CE, Hingorani SR. Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol. 2009;4(2):345–53.
Motoyoshi Y, Endo A, Takagi M, et al. Graft versus host disease-dependent renal dysfunction after hematopoietic stem cell transplantation. CEN Case Rep. 2014;3(2):202–5.
Mii A, Shimizu A, Kaneko T, et al. Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Pathol Int. 2011;61(9):518–27.
Kagoya Y, Kataoka K, Nannya Y, Kurokawa M. Pretransplant predictors and posttransplant sequels of acute kidney injury after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(3):394–400.
Liu H, Li YF, Liu BC, et al. A multicenter, retrospective study of acute kidney injury in adult patients with nonmyeloablative hematopoietic SCT. Bone Marrow Transplant. 2010;45(1):153–8.
de Fontbrune FS, Galambrun C, Sirvent A, et al. Use of Eculizumab in patients with allogeneic stem cell transplant-associated thrombotic Microangiopathy: a study from the SFGM-TC. Transplantation. 2015;99(9):1953–9.
Jodele S, Fukuda T, Vinks A, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow transplant: J Am Soc Blood Marrow Transplant. 2014;20(4):518–25.
Beyar-Katz O, Davila EK, Zuckerman T, et al. Adult nephrotic syndrome after hematopoietic stem cell transplantation: renal pathology is the best predictor of response to therapy. Biol Blood Marrow transplant: J Am Soc Blood Marrow Transplant. 2016;22(6):975–81.
Petropoulou AD, Robin M, Rocha V, et al. Nephrotic syndrome associated with graft rejection after unrelated double cord blood transplantation. Transplantation. 2010;90(7):801–2.
Fraile P, Vazquez L, Caballero D, et al. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant. Eur J Haematol. 2013;91(2):129–34.
Byrne-Dugan CJ, Collins AB, Lam AQ, Batal I. Membranous nephropathy as a manifestation of graft-versus-host disease: association with HLA antigen typing, phospholipase A2 receptor, and C4d. Am J Kidney Dis. 2014;64(6):987–93.
Mattei D, Sorasio R, Guarnieri A, et al. Long-term results of rituximab treatment for membranous nephropathy after allogeneic hematopoietic SCT: a case report. Bone Marrow Transplant. 2010;45(6):1111–2.
Hu SL, Colvin GA, Rifai A, et al. Glomerulonephritis after hematopoietic cell transplantation: IgA nephropathy with increased excretion of galactose-deficient IgA1. Nephrol Dial Transplant. 2010;25(5):1708–13.
Higo S, Shimizu A, Masuda Y, et al. Acute graft-versus-host disease of the kidney in allogeneic rat bone marrow transplantation. PLoS One. 2014;9(12):e115399.
Sadeghi B, Al-Chaqmaqchi H, Al-Hashmi S, et al. Early-phase GVHD gene expression profile in target versus non-target tissues: kidney, a possible target? Bone Marrow Transplant. 2013;48(2):284–93.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Bauer, A.R., Finn, L.S., Hingorani, S.R. (2019). Kidney Involvement in GVHD. In: Yeung, C., Shulman, H. (eds) Pathology of Graft vs. Host Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-42099-8_19
Download citation
DOI: https://doi.org/10.1007/978-3-319-42099-8_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42098-1
Online ISBN: 978-3-319-42099-8
eBook Packages: MedicineMedicine (R0)